The Short Version
Russia did administer its domestically developed personalized mRNA cancer vaccine, NeoOncovac, to a patient for the first time in April 2026 — but this was a national milestone, not a global first. Personalized cancer vaccines had already been administered to hundreds of patients in international clinical trials years earlier, as documented by the European Commission. The claim's phrasing implies a world-first achievement that the evidence does not support.